Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) Other Operating Expenses (2024 - 2026)

Intellia Therapeutics has reported Other Operating Expenses over the past 3 years, most recently at $904000.0 for Q1 2026.

  • Quarterly Other Operating Expenses fell 57.46% to $904000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$2.1 million through Mar 2026, up 94.19% year-over-year, with the annual reading at -$899000.0 for FY2025, 97.24% up from the prior year.
  • Other Operating Expenses was $904000.0 for Q1 2026 at Intellia Therapeutics, down from $1.8 million in the prior quarter.
  • Over five years, Other Operating Expenses peaked at $20.4 million in Q2 2024 and troughed at -$62.0 million in Q4 2024.
  • The 3-year median for Other Operating Expenses is $1.8 million (2025), against an average of -$3.6 million.
  • The largest YoY upside for Other Operating Expenses was 102.83% in 2025 against a maximum downside of 212.24% in 2025.
  • A 3-year view of Other Operating Expenses shows it stood at -$62.0 million in 2024, then soared by 102.83% to $1.8 million in 2025, then tumbled by 48.46% to $904000.0 in 2026.
  • Per Business Quant, the three most recent readings for NTLA's Other Operating Expenses are $904000.0 (Q1 2026), $1.8 million (Q4 2025), and -$3.4 million (Q3 2025).